Voyager Therapeutics PE Ratio 2014-2019 | VYGR

Current and historical p/e ratio for Voyager Therapeutics (VYGR) from 2014 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Voyager Therapeutics PE ratio as of June 25, 2019 is 0.00.
Voyager Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-06-25 25.80 0.00
2019-03-31 19.14 $-2.94 0.00
2018-12-31 9.40 $-2.76 0.00
2018-09-30 18.92 $-2.46 0.00
2018-06-30 19.54 $-2.72 0.00
2018-03-31 18.79 $-2.65 0.00
2017-12-31 16.60 $-2.67 0.00
2017-09-30 20.59 $-2.84 0.00
2017-06-30 8.96 $-2.30 0.00
2017-03-31 13.24 $-1.94 0.00
2016-12-31 12.74 $-1.58 0.00
2016-09-30 12.01 $-1.68 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.950B $0.008B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.245B 9.70
Mylan (MYL) United Kingdom $9.613B 4.20
Teva Pharmaceutical Industries (TEVA) Israel $8.959B 3.51
Bausch Health Cos (BHC) Canada $8.579B 5.86
Dr Reddy's Laboratories (RDY) India $6.022B 22.53
Supernus Pharmaceuticals (SUPN) United States $1.633B 16.33
Amphastar Pharmaceuticals (AMPH) United States $0.963B 53.87
Homology Medicines (FIXX) United States $0.823B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.704B 1.05
Akorn (AKRX) United States $0.585B 0.00
CymaBay Therapeutics (CBAY) United States $0.471B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.463B 0.00
Assembly Biosciences (ASMB) United States $0.354B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.264B 0.00
Sol-Gel Technologies (SLGL) Israel $0.180B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.162B 0.00
Acasti Pharma (ACST) Canada $0.083B 0.00
Agile Therapeutics (AGRX) United States $0.063B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.056B 0.00
Teligent (TLGT) United States $0.032B 0.00
Evoke Pharma (EVOK) United States $0.013B 0.00
China Pharma Holdings (CPHI) China $0.013B 0.00
Aevi Genomic Medicine (GNMX) United States $0.011B 0.00